CENBF (CEN Biotech) Equity-to-Asset: -0.36 (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CEN Biotech Equity-to-Asset?

CEN Biotech CENBF Equity-to-Asset is -0.36 as of Mar. 2023.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CEN Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-2.67 Mil. CEN Biotech's Total Assets for the quarter that ended in Mar. 2023 was $7.45 Mil. Therefore, CEN Biotech's Equity to Asset Ratio for the quarter that ended in Mar. 2023 was -0.36.

The historical rank and industry rank for CEN Biotech's Equity-to-Asset or its related term are showing as below:

CENBF's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.6
* Ranked among companies with meaningful Equity-to-Asset only.

CEN Biotech  (OTCPK:CENBF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

CEN Biotech Equity-to-Asset Related Terms

CEN Biotech Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for CEN Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEN Biotech Equity-to-Asset Chart

CEN Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only -2.91 -3.50 -1.58 -0.20 -0.29

CEN Biotech Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.23 -0.27 -0.29 -0.36

CENBF vs INLB, NEPT, SGBI: Equity-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEN Biotech Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where CEN Biotech's Equity-to-Asset falls into.


CEN Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

CEN Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-2.291/7.859
=-0.29

CEN Biotech's Equity to Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

Equity to Asset (Q: Mar. 2023 )=Total Stockholders Equity/Total Assets
=-2.672/7.447
=-0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -0.36 mean?
CEN Biotech (CENBF) has a Equity-to-Asset of -0.36 as of Mar. 2023. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CEN Biotech and its competitors.
Is CEN Biotech's Equity-to-Asset too high?
CEN Biotech's current Equity-to-Asset is -0.36.
How does CEN Biotech's Equity-to-Asset compare to INLB and NEPT?
CEN Biotech's Equity-to-Asset of -0.36 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CEN Biotech and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CEN Biotech's current Equity-to-Asset is -0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEN Biotech stock overvalued right now?
CEN Biotech (CENBF) has a current Equity-to-Asset of -0.36. The current Equity-to-Asset is -0.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CEN Biotech (CENBF), the current Equity-to-Asset is -0.36 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEN Biotech Business Description

Address 3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9
CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.